Changes in HCV therapy - approval of Sofosbuvir
Friday, 30 January 2015 13:55
Dr Stephen Ryder, BSG Vice-President Hepatology & Dr Andrew Austin, Chair BSG Liver Section
There are two major changes in HCV therapy which now have NICE and/or NHSE approval for use. The first is that commissioning guidance for the use of Simiprevir is published (http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-a/a02/). This allows G1 patients without Q80K to access triple therapy now using Simiprevir instead of Boceprevir or Telaprevir.
The second and probably more significant development is the approval of Sofosbuvir. The approval can be summarised as below:
Sofosbuvir in combination with pegylated interferon + ribavirin (Peg-IFN+RBV)
|HCV genotype||Adult patient population|
|Genotype 3||Treatment-naïve with cirrhosisa|
|Genotype 4, 5, or 6||Treatment-naïve & experienced with cirrhosisa|
Sofosbuvir in combination with RBV
|HCV genotype||Adult patient population|
|Genotype 3||Treatment-naïve with cirrhosisb|
|Treatment-experienced with cirrhosisb|
SAGE Awards, a national awards programme to recognise excellence in gastroenterology, is now accepting entries for 2015
Friday, 09 January 2015 09:58
The SAGE Awards - Shire Awards for Gastrointestinal Excellence, is now accepting entries for the 2015 Awards. This is the 5th year of the awards, which are supported by Shire and are designed to allow individual healthcare professionals, units and healthcare networks in gastrointestinal (GI) care to be recognised for innovative work, share best practice and raise standards of patient care. Three awards will be made in the form of financial grants to the amount of £10,000, £5,000 and £3,000, for use towards furthering the development of the winning projects. In 2014 the winning team was Dr Matthew Johnson's team at Luton & Dunstable for their IBD self-help programme.
Applications must be consultant led and will be accepted from all professional groups working in GI care, including patient representative groups working in collaboration with clinical teams. Collaborative projects bringing together professionals from two or more health board areas or across specialities, disciplines or sectors are also welcomed.
The awards judging panel will oversee the evaluation, assessment and awarding of the SAGE Awards and will be looking for entries that show innovation in the field of GI care and a significant improvement in patient care. The judging panel's assessment of entries, selection of evaluation criteria, meetings, deliberations and decisions are entirely independent of Shire.
BSG - BASL Decompensated Cirrhosis Care Bundle - First 24 Hours
Friday, 05 December 2014 10:30
Decompensated cirrhosis is a medical emergency with a high mortality. Effective early interventions can save lives and reduce hospital stay. This checklist should be completed for all patients admitted with decompensated cirrhosis within the first 6 hours of admission.
The recent NCEPOD report 2013 on alcohol related liver disease highlighted that the management of some patients admitted with decompensated cirrhosis in the UK was suboptimal. Admission with decompensated cirrhosis is a common medical presentation and carries a high mortality (10-20% in hospital mortality).
Early intervention with evidence-based treatments for patients with the complications of cirrhosis can save lives. This checklist aims to provide a guide to help ensure that the necessary early investigations are completed in a timely manner and appropriate treatments are given at the earliest opportunity.
Lancet liver recommendations must be implemented to address crisis
Tuesday, 25 November 2014 00:00
The British Society of Gastroenterology (BSG) has today urged for the Lancet Commission UK Liver Disease Publication recommendations to be pursued "without delay" to "address the UK liver disease crisis".
Liver Disease mortality rates have increased by 400% since 1970 and is the third most common form of premature death in the UK.
The most common form of liver disease is alcohol-related, followed by fatty liver disease caused by obesity. The steep rise in both alcohol consumption and obesity in recent decades has led to increases in both conditions.
Incidences of chronic viral hepatitis are also on the rise, with annual deaths from hepatitis C having quadrupled since 1996, and significant increases in hepatitis B infection.
The Lancet report calls for wide-reaching, joined-up action including:
- Better detection of early disease in primary care
- Improved support services in community settings
- The establishment of Liver Units in District General Hospitals
- A national review of liver transplantation services
- Strengthening of continuity of care for children with liver disease surviving into adult life
- A range of population-level measures such as a minimum unit price for alcohol
- Promotion of healthier lifestyles with clearer government messaging and new regulations on the food industry
- Eradication of chronic HBV and HCV infection from the country by 2020
- Greater provision of medical training in hepatology
- A national campaign led by NHS England to increase awareness of liver disease in the general population
Page 1 of 3